comparemela.com

Year Expense News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Eagle Pharmaceuticals Reports Third Quarter 2022 Results

07.11.2022 - Q3 2022 net loss was $(0.27) per basic and diluted share and adjusted non-GAAP net income was $1.13 per basic and $1.12 per diluted share1Total revenue for Q3 2022 was $65.9 million, compared to $39.9 million in Q3 2021Nine-month 2022 net income was .

Eagle Pharmaceuticals Reports Second Quarter 2022 Results

09.08.2022 - •   Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share •   Total revenue for Q2 2022 was $74.1 million, compared to $48.1 million in Q2 2021, primarily .

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.